The stock market finally hit some resistance on Tuesday, giving up ground and breaking a long streak of consecutive advances for most major benchmarks. Market participants got spooked by a rise in interest rates, with 10-year Treasury yields once again climbing above the 3% mark and leading some to predict even steeper advances in the future. With budget deficits ballooning, higher interest expenses on the national debt could have a dramatic impact on the U.S. economy, especially if it lures investors away from high-flying stocks. Yet even amid the bond-driven downturn, some individual companies saw good news lift their shares. Valeant Pharmaceuticals International (NYSE:VRX), Hollysys Automation Technologies (NASDAQ:HOLI), and Ascena Retail Group (NASDAQ:ASNA) were among the best performers on the day. Here’s why they did so well.
Valeant gets a good review
Shares of Valeant Pharmaceuticals International almost 4% after the drug company received favorable comments from analysts. Mizuho Securities raised its rating on Valeant from neutral to buy, pushing its price target higher by 80% to $27 per share. The pharma stock saw one of the most dramatic plunges in the industry in recent years, triggered by scandals about its business model, but Valeant has worked hard to reposition itself strategically to emphasize its highest-growth treatment prospects while restoring its reputation. Valeant still has a long way to go, but positive analysis from Wall Street is a sign that the drugmaker is making progress.
Hot High Tech Stocks To Buy Right Now: Helmerich & Payne, Inc.(HP)
- [By ]
Only 10% of the companies on the list had female CEOs at the helm, four of which — Hewlett Packard (HP) , Lockheed Martin (LMT) , General Motors (GM) , and General Dynamics (GD) — grew significant revenue in five years or less.
- [By Garrett Baldwin]
On Tuesday, the Trump administration said it would press ahead with 25% tariffs on roughly $50 billion in Chinese goods. As U.S. Trade Secretary Wilbur Ross prepares to head to Beijing to discuss trade this week, the Trump administration is demanding that China address ongoing theft of U.S. intellectual property.
Ahead of Friday’s jobs report, Automatic Data Processing (NYSE: ADP) reported that private jobs increased by 178,000 during May. That figure was actually 12,000 behind what the markets were anticipating. Job growth appears to be slowing down as the firm also revised its jobs figure for April downward, from 204,000 new positions to 163,000.
Three Stocks to Watch Today: KORS, HP, KMI
Michael Kors Holdings Ltd.(NYSE: KORS) stock was off 3.2% in pre-market hours after the company reported earnings before the bell. The luxury retailer reported earnings per share (EPS) of $0.63, a figure that topped Wall Street expectations of $0.60. The firm also beat revenue expectations and reported an increase in same-store sales. However, the firm’s earnings forecast for the year ahead came in lower than expectations, a factor that pushed its stock lower on Wednesday morning.
Shares of HP Inc. (NYSE: HP) were up slightly after the company raised its full-year outlook and topped Wall Street earnings expectations on Tuesday. The company cited stronger demand in desktops and notebooks for its financial performance. The firm matched EPS expectations of $0.48. However, revenue came in at $14.0 billion, a figure that easily beat forecasts of $13.59.
The Canadian government announced plans to purchase the Trans Mountain pipeline from Kinder Morgan Canada Ltd. (NYSE: KML) for $3.5 billion. The Canadian government said that the deal was the only way to ensure that the long-awaited project could proceed. The pipeline runs from the Alberta oil sands to a port all the way in British Columbia along the Pacific Ocean. The pipeline is designed to give Canadian crude grea
- [By Shane Hupp]
Helmerich & Payne, Inc. (NYSE:HP) – Analysts at Jefferies Financial Group issued their Q1 2019 earnings estimates for Helmerich & Payne in a research note issued on Tuesday, June 19th. Jefferies Financial Group analyst B. Handler forecasts that the oil and gas company will post earnings of $0.24 per share for the quarter. Jefferies Financial Group has a “Buy” rating and a $80.00 price objective on the stock. Jefferies Financial Group also issued estimates for Helmerich & Payne’s Q2 2019 earnings at $0.25 EPS, Q3 2019 earnings at $0.43 EPS and Q4 2019 earnings at $0.62 EPS.
- [By Chris Johnson]
Let me show you…
I Love Helmerich & Payne Inc. (NYSE: HP) for This Coming Week
My trading model is practically screaming to recommend this contract petroleum drilling company.
- [By Max Byerly]
Here are some of the media headlines that may have effected Accern Sentiment’s rankings:
Get Helmerich & Payne alerts:
YieldBoost Helmerich & Payne From 4.2% To 8.4% Using Options (nasdaq.com) HP Stock Crowded With Sellers (nasdaq.com) Helmerich & Payne – In Need Of A Better Profit Margin (seekingalpha.com) Crude Oil Futures: Drivers on June 48 (finance.yahoo.com) Brokerages Expect Helmerich & Payne, Inc. (HP) Will Announce Quarterly Sales of $614.29 Million (americanbankingnews.com)
A number of equities research analysts have issued reports on the stock. ValuEngine upgraded shares of Helmerich & Payne from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. Zacks Investment Research cut shares of Helmerich & Payne from a “buy” rating to a “hold” rating in a report on Wednesday, March 7th. TheStreet cut shares of Helmerich & Payne from a “b-” rating to a “c” rating in a report on Thursday, April 26th. Credit Suisse Group upped their price objective on shares of Helmerich & Payne from $51.00 to $63.00 and gave the company a “market perform” rating in a research report on Friday, April 27th. Finally, Susquehanna Bancshares raised shares of Helmerich & Payne from a “neutral” rating to a “positive” rating and upped their price objective for the company from $42.16 to $75.00 in a research report on Friday, March 9th. Five analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $58.42.
- [By ]
The third caller had Boeing (BA) , Helmerich & Payne (HP) , Fiat Chrysler (FCAU) , LAM Research (LRCX) and Steel Dynamics (STLD) as her top five stocks.
Hot High Tech Stocks To Buy Right Now: Cincinnati Financial Corporation(CINF)
- [By Ethan Ryder]
Swiss National Bank lowered its holdings in Cincinnati Financial (NASDAQ:CINF) by 13.6% in the first quarter, HoldingsChannel reports. The firm owned 498,032 shares of the insurance provider’s stock after selling 78,400 shares during the quarter. Swiss National Bank’s holdings in Cincinnati Financial were worth $36,984,000 as of its most recent SEC filing.
- [By Ethan Ryder]
WealthPLAN Partners LLC grew its holdings in Cincinnati Financial Co. (NASDAQ:CINF) by 45.5% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 33,842 shares of the insurance provider’s stock after acquiring an additional 10,584 shares during the quarter. WealthPLAN Partners LLC’s holdings in Cincinnati Financial were worth $2,513,000 at the end of the most recent reporting period.
- [By Logan Wallace]
FDx Advisors Inc. decreased its holdings in Cincinnati Financial (NASDAQ:CINF) by 14.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,572 shares of the insurance provider’s stock after selling 7,490 shares during the period. FDx Advisors Inc.’s holdings in Cincinnati Financial were worth $3,236,000 at the end of the most recent reporting period.
- [By Joseph Griffin]
Trexquant Investment LP purchased a new stake in shares of Cincinnati Financial (NASDAQ:CINF) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 7,604 shares of the insurance provider’s stock, valued at approximately $565,000.
Hot High Tech Stocks To Buy Right Now: Biogen Idec Inc(BIIB)
- [By Brian Feroldi]
Data source: Alkermes. GAAP = generally accepted accounting principles.
What happened with Alkermes this quarter?
Sales of Alkermes’opioid- and alcohol-abuse prevention drug Vivitrol grew 7% to $62.7 million. Sales of the company’sschizophrenia drugAristadarose 62% to $29.2 million. Manufacturing and royalty revenue related toJohnson & Johnson’s schizophrenia drugs jumped 15% to $68.8 million. Manufacturing and royalty revenue related toAcorda Therapeutics’ multiple sclerosis drugfell3% to $28.3 million. Research and development revenue earned as part of its collaboration withBiogen (NASDAQ:BIIB) for BIIB098 — which used to be called ALKS 8700 — was $17.5 million.
Looking beyond the financials, here’s an overview of the key events from the period:
- [By Brian Orelli]
Shares of Ionis Pharmaceuticals (NASDAQ:IONS) ended the day down 10.6% after an earnings reportfrom partner Biogen (NASDAQ:BIIB) started the day on a sour note. Then shares dropped even further midday after data was releasedfor IONIS-HTTRx, a treatment for Huntington’s disease. Biogen managed to end the day in the green, up 1.1%.
- [By Chris Lange]
Biogen Inc. (NASDAQ: BIIB) is expected to report its first-quarter results early on Tuesday. The consensus forecast calls for $5.92 in earnings per share (EPS) and revenue of $3.15 billion. Shares of Biogen ended last week at $263.02. The consensus analyst price target is all the way up at $371.97. The 52-week trading range is $244.28 to $370.57.
- [By Keith Speights]
This has been a bad year for Biogen (NASDAQ:BIIB) so far — the biotech’s stock has dropped more than 10% since it began. But 2018 has been horrible for Acadia Pharmaceuticals (NASDAQ:ACAD), which has seen its share price plunge nearly 40%.
- [By Cory Renauer]
Biotech traders get heaps of attention, but buying promising young drugmakers and holding them for the long term is a far easier way to get rich. Case in point: Spreading $10,000 evenly among shares of Biogen Inc. (NASDAQ:BIIB),Celgene Corporation (NASDAQ:CELG), andGilead Sciences Inc.(NASDAQ:GILD) around this time in 1998 would have made you a millionaire already.